Report: Target Product Profiles: Physician Insights on Key Attributes - Dyslipidemia, An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia. TOC

Target Product Profiles: Physician Insights on Key Attributes - Dyslipidemia, An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia.

Published by

Decision Resources, Inc.

Published

2008/03

Content info

44 Pages

Product code

DR65855

Price

From US $ 5625

PDF by E-Mail

Approx. 1-2 business days

Hard Copy/CD-ROM

Approx. 3-4 business days

If you need expedited delivery, please call us.

Introduction
- Using Target Product Profiles in Your Market Strategy
- Report Contents
- Target Product Profile Methodology
Etiology and Pathophysiology
- Overview
  - Lipid Pathways and Mechanisms
  - Types of Lipoprotein and Lipoprotein Components
  - Lipoprotein Generation and Transport
- Pathophysiology
  - Dyslipidemia and Cardiovascular Disease Risk
  - Cardiovascular Disease Markers in Dyslipidemia and Atherosclerosis
- Etiology
  - Primary Dyslipidemia
  - Secondary Dyslipidemia
Target Product Profile Discussion-Dyslipidemia
- Target Product Profile Summary for Dyslipidemia-2011
- Assessing Drug Development Opportunities
- Physician Survey Results
  - Effi cacy
  - Safety and Tolerability
  - Delivery
  - Estimated Patient Share
- Pricing Potential
- Forecasted 2016 Pricing Environment
- Competitors to Watch
- Emerging Product Profiles

Target Product Profiles: Physician Insights on Key Attributes - Dyslipidemia, An HDL-raising drug that has a lower discontinuation rate than extended-release (ER) niacin for the treatment of dyslipidemia.

Table of Contents